MedPath

Pamiparib

Generic Name
Pamiparib
Drug Type
Small Molecule
Chemical Formula
C16H15FN4O
CAS Number
1446261-44-4
Unique Ingredient Identifier
8375F9S90C
Background

Pamiparib is under investigation in clinical trial NCT03933761 (Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy).

Indication

用于既往经过二线及以上化疗的伴有胚系BRCA(gBRCA)突变的复发性晚期卵巢癌、输卵管癌或原发性腹膜癌患者的治疗。

Clinical Trials
Related News

Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors

Phase 1
Active, not recruiting
Conditions
Refractory Malignant Solid Neoplasm
Advanced Malignant Solid Neoplasm
Interventions
First Posted Date
2021-09-09
Last Posted Date
2025-05-02
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
44
Registration Number
NCT05038839
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

A Trial of Pamiparib With Tislelizumab in Patients With Advanced Tumours With Homologous Recombination Repair Defects

Phase 2
Recruiting
Conditions
Cancer
Interventions
First Posted Date
2021-08-02
Last Posted Date
2023-03-15
Lead Sponsor
Peter MacCallum Cancer Centre, Australia
Target Recruit Count
60
Registration Number
NCT04985721
Locations
🇦🇺

Austin Hospital, Heidelberg, Victoria, Australia

🇦🇺

St Vincent's Hospital, Fitzroy, Victoria, Australia

🇦🇺

Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

Pamiparib and Low Dose Temozolomide In Patients With Platinum Sensitive Biliary Tract Cancer

Phase 2
Withdrawn
Conditions
Platinum-Sensitive Biliary Tract Cancer
Interventions
First Posted Date
2021-03-12
Last Posted Date
2022-06-01
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Registration Number
NCT04796454

Study of Pamiparib in Newly Diagnosed and RGBM

Early Phase 1
Active, not recruiting
Conditions
Glioblastoma
Glioblastoma Multiforme
Glioblastoma Multiforme, Adult
Interventions
Radiation: Radiation therapy
First Posted Date
2020-11-04
Last Posted Date
2025-02-28
Lead Sponsor
Nader Sanai
Target Recruit Count
45
Registration Number
NCT04614909
Locations
🇺🇸

St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States

Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer

Phase 2
Withdrawn
Conditions
Clear Cell Papillary Renal Neoplasm
Hereditary Leiomyomatosis and Renal Cell Carcinoma
Collecting Duct Carcinoma
Metastatic Unclassified Renal Cell Carcinoma
Papillary Renal Cell Carcinoma
Stage III Renal Cell Cancer American Joint Committee on Cancer (AJCC) v8
Unresectable Renal Cell Carcinoma
Hereditary Papillary Renal Cell Carcinoma
Metastatic Renal Cell Carcinoma
Stage IV Renal Cell Cancer AJCC v8
Interventions
First Posted Date
2020-10-26
Last Posted Date
2023-05-17
Lead Sponsor
Jonsson Comprehensive Cancer Center
Registration Number
NCT04603365

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

First Posted Date
2019-11-15
Last Posted Date
2025-05-09
Lead Sponsor
BeiGene
Target Recruit Count
430
Registration Number
NCT04164199
Locations
🇨🇳

Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China

🇺🇸

Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States

🇺🇸

Memorial Sloan Kettering Cancer Center Mskcc, New York, New York, United States

and more 103 locations

Study to Investigate the Effect of Rifampin and Itraconazole on the Action of Pamiparib in Participants With Cancer

First Posted Date
2019-06-21
Last Posted Date
2024-10-26
Lead Sponsor
BeiGene
Target Recruit Count
25
Registration Number
NCT03994211
Locations
🇬🇪

Arensia Exploratory Medicine Llc, Tbilisi, Georgia

🇵🇱

Szpital Luxmed, Warszawa, Poland

🇸🇰

Summit Clinical Research, Sro, Bratislava, Slovakia

and more 1 locations

Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy

Phase 2
Withdrawn
Conditions
Ovarian Cancer
Carcinosarcoma
Interventions
First Posted Date
2019-05-01
Last Posted Date
2021-08-10
Lead Sponsor
Australia New Zealand Gynaecological Oncology Group
Registration Number
NCT03933761

Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency

Phase 2
Terminated
Conditions
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Homologous Recombination Deficiency (HRD)
Interventions
First Posted Date
2018-10-19
Last Posted Date
2021-11-17
Lead Sponsor
BeiGene
Target Recruit Count
13
Registration Number
NCT03712930
Locations
🇺🇸

University of Washington, Seattle, Washington, United States

🇦🇺

Liverpool Hospital, Liverpool, New South Wales, Australia

🇺🇸

University Cancer and Blood Center, Athens, Georgia, United States

and more 6 locations

Efficacy and Safety of BGB-290 in the Treatment of Metastatic HER2-Negative Breast Cancer Patients With BRCA Mutation in China

Phase 2
Completed
Conditions
HER2-negative Breast Cancer
Interventions
First Posted Date
2018-07-02
Last Posted Date
2024-10-26
Lead Sponsor
BeiGene
Target Recruit Count
88
Registration Number
NCT03575065
Locations
🇨🇳

Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China

🇨🇳

Sun Yat Sen Memorial Hospital, Sun Yat Sen University (North), Guangzhou, Guangdong, China

🇨🇳

Sun Yat Sen University Cancer Center, Guangzhou, Guangdong, China

and more 17 locations
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy